Physician profile
Timothy Grose Harper
NPI 1659467579
$188.29
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $34.17.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $91.95 | 2019 | |
| Shionogi INC | $21.36 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.28 | 2020 | |
| Mallinckrodt Hospital Products INC. | $15.89 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.81 | 2019 | |
| Abbott Laboratories | $13.38 | 2019 | |
| Pfizer INC. | $11.62 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.